Comparative Pharmacology
Head-to-head clinical analysis: MD 60 versus OXILAN 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 60 versus OXILAN 300.
MD-60 vs OXILAN-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-60 is a nonionic iodinated contrast agent. It attenuates X-rays by increasing the density of structures and organs, improving radiographic visualization.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
Intravenous administration, 60 mg/kg as a single dose over 30 min.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function (CrCl >90 mL/min); prolonged to >40 hours in moderate renal impairment (CrCl 30–60 mL/min), requiring dose adjustment.
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Primarily renal elimination of unchanged drug (~60% within 24 hours) via glomerular filtration; biliary/fecal excretion accounts for ~30% as metabolites; ~10% undergoes enterohepatic recirculation.
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent